Business
Lisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and Development
Expanded alliance combines Lisata’s drug development expertise with GATC’s AI-powered Multiomics Advanced Technology® platform to accelerate and improve success rates of next-generation drug development Lisata to lead development efforts to advance GATC’s AI-discovered therapeutic for opioid use disorder into human clinical trials early in 2026 BASKING RIDGE, N.J. and IRVINE, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinica
About this update from Lisata Therapeutics, Inc.
[{"type":"image","alt":"Lisata Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Lisata Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":84,"url":"https://media.zenfs.com/en/globenewswire.com/67f4449bf2ef469a75e1732240c6e363"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/y4XbqVAm8oIdeBK9.mjRkg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/67f4449bf2ef469a75e1732240c6e363","width":300,"height":84}},"lazy":false},{"type":"text","content":"Expanded alliance combines Lisata’s drug development expertise with GATC’s AI-powered Multiomics Advanced Technology® platform to accelerate and improve success rates of next-generation drug development","length":202,"tagName":"p"},{"type":"text","content":"Lisata to lead development efforts to advance GATC’s AI-discovered therapeutic for opioid use disorder into human clinical trials early in 2026","length":143,"tagName":"p"},{"type":"text","content":"BASKING RIDGE, N.J. and IRVINE, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, and GATC Health Corp. (“GATC”), a leading tech-bio company leveraging artificial intelligence (AI) to transform drug discovery and development, today announced a strategic alliance designed to accelerate and improve the success rate of the traditional drug development process.","length":564,"tagName":"p"},{"type":"text","content":"This collaboration builds on the foundation of earlier work performed by GATC for Lisata, in which GATC provided AI-derived analysis in support of Lisata’s certepetide drug candidate. Under the expanded relationship, Lisata will enhance its therapeutic pipeline by leveraging GATC’s proprietary Multiomics Advanced Technology® (MAT) platform to identify new AI-predicted combination therapies (including with certepetide) across all therapeutic areas. This approach not only opens the door to new treatment possibilities but also ensures that any resulting intellectual property will be derisked by the MAT analysis, providing predictions of safety, efficacy and side effects with a high degree of certainty.","length":708,"tagName":"p"},{"type":"text",...